Introduction: Despite the therapeutic effectiveness of biologics targeting immune cells or
cytokines in patients with inflammatory arthritis, which reflects their pathogenic roles, an …

Clinicians should be aware of the risk for viral reactivation of an underlying chronic viral
infection during immunosuppressive therapy. Despite the existence of such risk, the …

METHODS: This was a territory-wide observational cohort study in Hong Kong. We identified
patients through electronic medical records based on the prescriptions of immune …

Background & Aims Systemic corticosteroids may cause HBV reactivation, but the impact on
patients with previous HBV exposure is poorly defined. We aimed to study the risk of HBsAg …

BACKGROUND & AIMS: HBV infection might reactivate in the setting of
immunosuppression, although the frequency and consequences of HBV reactivation are not …

Hepatitis B reactivation is a major cause of morbidity and mortality in patients undergoing
chemotherapy for lymphomas. These patients may experience direct liver‐related …

Background Systemic corticosteroid is used for different medical conditions and may cause
hepatitis B virus (HBV) reactivation. Aims To study the impact of duration and peak dose of …

Objective To assess the degree of awareness of the American College of Rheumatology
(ACR) guidelines and package insert information on the screening for and management of …

The recent introduction of direct-acting antiviral drugs (DAAs) for treatment of the hepatitis C
virus (HCV) has greatly improved the management of HCV for infected patients. These viral …

Hepatitis B virus (HBV) is one of the public-health issues worldwide. Approximately two
billion people are infected with HBV, and about 350 million people are chronic carriers …